CDSCO panel nod to Biological E to conduct Phase II trial of vaccine for 6- 8 weeks-old infants - Video
|
Overview
Reviewing the Phase I clinical trial report, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the vaccine maker Biological E to conduct a Phase II clinical trial of Diphtheria, Tetanus, Pertussis (Whole cell), Hepatitis B (rDNA), inactivated Poliomyelitis and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed) for 6- 8 weeks-old infants.
This came after the vaccine maker Biological E presented its proposal for the conduct of a Phase II clinical trial in 6- 8 weeks-old infants along with a Phase I clinical trial report.
For the full story, check out the link given below:
Biological E Gets CDSCO Panel Nod To Study Vaccine For 6- 8 Weeks Old Infants
Speakers
Anshika Mishra is a dedicated scholar pursuing a Masters in Biotechnology, driven by a profound passion for exploring the intersection of science and healthcare. Having embarked on this academic journey with a passion to make meaningful contributions to the medical field, Anshika joined Medical Dialogues in 2023 to further delve into the realms of healthcare journalism.